



EuroSIDA Newsletter

April 2022

Dear EuroSIDA Study Investigators,

Many greetings to all of you from the EuroSIDA coordinating office.

As we are moving towards a more sustainable situation with Covid-19, we hope you have gotten well into the new year. We are happy to send you the first EuroSIDA newsletter of this year with some updates that might be interesting for you.

Study updates

Cohort 11

As of March 2022, approximately 1,500 participants have been enrolled in Cohort 11. Enrolment will close in May 2022, and we expect to enroll 200 additional participants. We thank all the sites for your tremendous contribution to the study.

Dataset 49 (DS49)

The DS49 data collection finished in January.

Approximately 7,500 completed follow-up forms were collected in REDCap and follow-up data on additional 3,000 participants were also submitted via the REST submission system. In total, we have received follow up data on approximately 10,500 out of 14,000 participants under follow up.

Thank you for submitting your data and meeting the deadline. Please remember to complete the RESPOND event forms, CoDe forms and Cabotegravir forms (see below) before the end of April, as the reimbursement process will begin on 1 May 2022.

Clinical Reporting Form Updates

Covid 19 form

The Covid-19 form was introduced with the dataset 48 collection in REDCap for participants who had a positive PCR test and have been admitted to hospital for treatment of COVID-19. We have received forms from approximately 70 participants. However, there are still forms left to be completed, so please remember the deadline for reimbursement is 1 May 2022. For each form completed, 50 Euro will be reimbursed.

You can read more about the form in the [COVID-19 eCRF Manual of Operations here](#).

Cabotegravir

In 2021, with the collection of D49, EuroSIDA started to collect detailed data on participants who are receiving treatment with injectable long-acting cabotegravir and/or long-acting rilpivirine. Data are collected annually in two separate REDCap forms. The sub-study will run for five years. So far, only a total of 13 participants have started the forementioned treatment.

MISTRAL study

The MISTRAL study has reached to the process of finalizing the data processing agreement and site agreement and they have been sent to the sites. Enrolment is planned to start before the summer. More information on MISTRAL study [click here](#).

Reminders

Reimbursement will take place in June this year. Please make sure to complete Event forms in REDCap (CoDe forms, Cabotegravir forms, Covid-19 forms, enrolment forms) by 1 May 2022 to receive compensation in 2022.

Publications and Presentations

EuroSIDA reaches 322 Publications

As of March 2022, the EuroSIDA study group has published 322 manuscripts, 6 of which were published since November 2021.

This is a great achievement and we want to thank you for your significant contribution to the EuroSIDA study and the global community of people living with HIV. A list of all EuroSIDA publications can be found [here](#).

Furthermore, two more manuscripts have been listed on behalf of the RESPOND Study Group. All RESPOND publications can be found [here](#).

EuroSIDA and RESPOND Presentations at The Conference on Retroviruses and Opportunistic Infections (CROI), February 2022

- A poster presentation on **HIV/HBV/HCV triple infection, end stage liver disease and all-cause mortality** was presented virtually by Amanda Mocroft on behalf of EuroSIDA Study Group. The presentation can be found [here](#).
- Two poster presentation on **Trends in cancer incidence in different modern ART-eras among people living with HIV**. You can find an annual overview of RESPOND presentations [here](#).

EuroSIDA Investigators meeting in Glasgow, October 2022

We are very excited to announce that we are planning to host our usual annual EuroSIDA investigator meeting in Glasgow which will be in conjunction with the conference.

We will touch upon updates in the EuroSIDA, MISTRAL and RESPOND study. Also, we will take the opportunity to celebrate the collection of EuroSIDA study data set 50 with cake to all the attendees. We are really looking forward to seeing many of you again. More information regarding the scientific scope of EuroSIDA will be announced in the next newsletter.

Stay tuned!

EuroSIDA Staff Update

Please welcome new and say goodbye to old colleagues at CHIP.

Ammar Ahmed has started as a project coordinator in the cohort group and will primarily work with the MISTRAL project. He has an MSc in Public Health from the University of Southern Denmark and experience as a project coordinator and research assistant with clinical trials and EU funded projects within UNICEF.

Malalai Gardizi has also joined the cohort group as project coordinator. She has an MSc in Human Nutrition from the University of Copenhagen and has most recently been working on projects related to nutrition at Rigshospitalet.

Unfortunately, we will be saying goodbye to our Project Assistant, **Ane Bojesen** in the cohort team. It has truly been a pleasure to be working with her. We wish her well and thank her for her great contributions to CHIP and, the EuroSIDA study over the past many years in particular.

Change in Centre Staff

As usual please remember to update the EuroSIDA Coordinating Centre if there are changes to staff. This allows all correspondence (information, newsletters, etc.) to be sent to the right contact person. It also allows the EuroSIDA Coordinating Centre to maintain the study group and correctly award co-authorship. Furthermore, if staff no longer work at your Centre or new staff members join your team, we will remove or assign REDCap access accordingly.

Why are you receiving this email?

You are receiving this email because you are affiliated with the EuroSIDA study. By providing your contact details to the EuroSIDA Coordinating Centre, you are included in the mailing list for the EuroSIDA study.

Contact

Please always feel free to contact the EuroSIDA coordinating centre at eurosida.rigshospitalet@regionh.dk. No question is too small or too big, we are happy to assist in all matters!

Copyright © 2021 Rigshospitalet, CHIP, All rights reserved.

You are receiving this email because you are affiliated with the EuroSIDA study.

Our mailing address is:

Rigshospitalet - University of Copenhagen

CHIP, Section 2100

Blegdamsvej 9

DK-2100 Copenhagen Ø,

Denmark

Want to change how you receive these emails?

You can update your preferences or unsubscribe from this list.